1 |
Generation of recombinant human respiratory syncytial viruses to study antigenic subtype differences, attachment glycoprotein evolution, and polymerase localizationOlinger, Grace Y. 01 November 2017 (has links)
Human respiratory syncytial virus (HRSV) is a negative sense, single strand RNA virus that causes respiratory tract infection with common cold-like symptoms, which can be severe in children, immunocompromised, and the elderly. Even with 60 years of research, the need for vaccine and effective treatment has not been met. In this work, recombinant viruses have been generated which will be valuable in gaining a better understanding of HRSV subtypes, glycoprotein evolution, and the polymerase localization, which would contribute to HRSV vaccine and therapeutics development.
The differences in the fitness of A and B antigenic subtypes of HRSV and how it affects the regional circulation pattern is not well understood. To study and compare the two subtypes, it is important to use clinically relevant recombinant viruses and to use animal models that best represent human infection. Using a wild-type virus strain (A11 and B05) from each HRSV subtype, a wild-type like recombinant (r) virus, rHRSVA11, and recombinant viruses expressing fluorescent proteins, rHRSVA11EGFP(5) and rHRSVB05dTom(5), were generated. Characterization of rB05 viruses demonstrated that the differences in the fluorescent protein expressed did not affect virus growth kinetics. To prepare for an experiment in cotton rats, recombinant HRSVs generated were used to infect cotton rat lung cells in vitro. With confirmation of infection of cotton rat lung cells by rHRSV, cotton rat co-infection experiment was planned for the recombinant A11 and B05 viruses and a microneutralization assay was developed for post-infection processing of the in vivo samples.
The BA genotype of HRSV B subtype is a strain of HRSV B subtype containing a 60 nucleotide duplication in the glycoprotein (G) gene. HRSV BA genotype was first isolated in 1998 and has quickly become the predominant genotype circulating globally. Although a role of immune evasion by the strains of BA genotype has been suggested to explain this phenomenon, few studies have supported this hypothesis. To compare the HRSV B subtype virus with and without the duplication, rB05 virus lacking the duplication, rHRSVB05EGFP(5)GΔ60b, and containing an epitope tag within the duplication, rHRSVB05EGFP(5)Gmycb, were generated. A serial passage experiment was set up using rHRSVB05EGFP(5) and rHRSVB05EGFP(5)GΔ60b to understand the mutations that accumulate in the G protein gene of each virus. This will be valuable in setting up a similar experiment in the presence of immune pressure to understand the advantage that is conferred to the virus containing the duplication. Expression of Gmyc was confirmed in rHRSVB05EGFP(5)Gmyc infection, which validated that this virus can be used to study the HRSVB05 G protein and modifications in the duplicated region.
The HRSV large (L) protein is essential in HRSV transcription and replication, but is difficult to study due to lack of immunologic reagents and challenges with purification. Recombinant viruses expressing reporter and polymerase fusion proteins have been generated and used for studying various other viral polymerases. Expression plasmids for HRSV L protein containing a reporter protein in its variable region 2 have been published. However, the modification resulted in downregulation in the function of the protein and rHRSV expressing modified L protein have not yet been published. In this study, rHRSVB05LVenus was generated to study the effects of modification of HRSV L protein variable region and the localization of HRSV L protein. LVenus protein in rHRSVB05LVenus infected cells was visualized by confocal laser scanning microscopy and the expression levels were examined by immunoblotting. rHRSVB05LVenus was compared to rHRSVB05EGFP(5) with unmodified L protein to show that modification of HRSV L protein had no effect on virus replication. Viruses had equivalent growth kinetics and were equally sensitive to ribavirin, a known HRSV inhibitor.
The recombinant viruses generated in this study are valuable tools in answering questions that are difficult to pursue without clinically relevant recombinant viruses. Characterization of the rHRSVs demonstrated that these viruses will have many applications. In this study, viruses were characterized for the basic growth kinetics, expression of proteins of interest, and assay development. With these validated tools, questions such as the cause of the epidemiological pattern observed for HRSV A and B subtypes, the role of host immune response in advantage conferred to HRSV BA genotype, and the effects of inhibitors to formation of HRSV polymerase complex can be addressed. / 2018-10-31T00:00:00Z
|
2 |
Charakterizace příspěvku genu gag k celkové replikační zdatnosti HIV u pacientů s různým průběhem nemoci / Contribution of gag region to overall HIV replicative fitness in patients with different disease progressionSuchý, Tomáš January 2017 (has links)
Human immunodeficiency virus (HIV) is globally spread virus without available cure. Since its life-long presence, virus is carefully monitored as well as patient's immunological status. Replicative fitness of the virus is one of important aspects which can be taken into account, when monitoring HIV. Here, we are measuring HIV replicative fitness of gag recombinant viruses and comparing the results with replicative fitness of primary isolates. Further, we are comparing our findings of replicative fitness change over time with disease progression in the patient. We found that gag can be major contributor to overall fitness, although not in all cases. Additionally, we observed a correlation of replicative fitness development and slope of patient's CD4+ T cells. Moreover, this relation was even more noticeable in patients with slow disease progression or in carriers of protective alleles. In summary, our results extend the understanding of replicative fitness and its role in disease progression; and pave the way to use the recombinant HIV for replicative fitness measurement in clinical practice. Keywords: HIV, replicative fitness, recombinant virus, HIV disease progression, gag
|
3 |
Vacinologia e patogenicidade de amostras recombinantes de herpesvírus bovino tipo 1 (BoHV-1) / Vaccinology and pathogenicity of recombinants strains of the bovine herpesvirus type 1 (BoHV-1)Silva, Alessandra D'Avila da January 2007 (has links)
O herpesvírus bovino tipo 1 (BoHV-1) é um dos principais agentes causadores de prejuízos econômicos em criações de bovinos. A vacinação tem sido amplamente utilizada para minimizar as perdas causadas por infecções pelo BoHV-1. Dentre as vacinas disponíveis, as vacinas desenvolvidas a partir de amostras virais recombinantes apresentam a vantagem de permitirem a diferenciação entre animais infectados e imunizados. Anteriormente, foi desenvolvida uma vacina recombinante diferencial com uma amostra de BoHV-1 brasileira baseada na deleção do gene que codifica a glicoproteína E (gE). No primeiro capítulo do presente trabalho, a segurança e imunogenicidade desta vacina recombinante inativada foi avaliada. Os experimentos de imunização, desafio e reativação da vacina diferencial em animais experimentalmente inoculados demonstraram que a vacina recombinante foi segura e eficiente ao minimizar ou mesmo prevenir os efeitos da infecção pelo BoHV-1. No segundo capítulo, a segurança da vacina gE- foi avaliada, através da imunização intramuscular (IM) de 22 vacas (14 BoHV-1 soronegativas e 8 soropositivas) prenhes. Foi observada soroconverão, mas não abortos e nem anormalidades fetais nos animais imunizados. Na segunda parte do mesmo estudo foi analizada a capacidade do vírus recombinante difundir-se em um rebanho bovino. Quatro terneiros foram inoculados pela rota intranasal (IN) com a amostra recombinante gE- e, posteriormente, adicionados a outros 16 animais com mesma idade e semelhante condição corporal durante 180 dias. Todos os animais foram monitorados diariamente em busca de sintomatologia clínica. Foi observada soroconversão apenas nos animais imunizados. Estes resultados indicam que, nas condições deste estudo, a amostra recombinante não causou nenhum dano nas vacas prenhes ou em seus terneiros e não foi capaz de difundir-se horizontalmente no rebanho. No terceiro capítulo foi avaliada a patogenicidade de uma amostra recombinante de BoHV-1 com deleção no gene Us9, utilizando coelhos como modelo experimental. Coelhos com quatro semanas de idade foram divididos em quatro grupos (A, B, C, D). Dois grupos (A e B) foram infectados via intranasal (IN) e dois (C e D) infectados via intraocular (IO). Em cada via de infecção, um grupo foi infectado com o vírus recombinante e o outro com o vírus selvagem (wt). Após a infecção IO, todos os animais, de ambos os grupos, desenvolveram intensa conjuntivite entre os dias 3 a 10 pós-inoculação (pi). Vírus infeccioso foi consistentemente isolado a partir dos suabes oculares entre os dias 1 a 10 pi chegando a um título máximo de 103,05 TCID50/mL. Nos grupos infectados pela via IN com BoHV-1 wt, 4/4 coelhos apresentaram sintomatologia característica da doença, tais como: pirexia, apatia, anorexia, tosse, secreção nasal severa (entre os dias 2 e 8 pi). Animais inoculados com o recombinante apresentaram apatia, anorexia e descarga nasal (entre os dias 3 e 7 pi). Vírus infeccioso foi isolado em diversos tecidos tanto nos animais inoculados com o vírus wt como recombinante. Ambos os vírus foram capazes de replicar nas mucosas. Análises histológicas dos tecidos dos animais demonstraram lesões em ambos os grupos. Este estudo apresentou que a proteína Us9 não tem um papel significante na patogenicidade in vivo. / Bovine herpesvirus type 1 (BoHV-1) is an the major cause of losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. Vacines developed from recombinant strains have the advantage of allow the differentiation between immunized and infected animals. Previously, a recombinant differential BoHV-1 vaccine based on a glycoprotein E deleted (gE) virus was developed. In the first chapter of the present work, the safety and immunogenicity of such recombinant, as a inactivate vaccine, was evaluated. The experiments showed that the DIVA vaccinne was safe and efficient in order to minimize or even prevent the clinical signs of the infection by BoHV- 1. In the second chapter of the present study, the safety of the gE- vaccine during pregnancy was evaluated by the intramuscular inoculation into 22 pregnant dams (14 BoHV-1 seronegative; 8 seropositive). Seroconversion was detected but no abortions, stillbirths or fetal abnormalities were seen after vaccination. In the second part of the same study, the potential of the gE- vaccine virus to spread among beef cattle under field conditions was examined. Four heifers were inoculated intranasally (IN) with the gE- vaccine and mixed with other 16 animals at the same age and body conditions, for 180 days. All animals were daily monitored for clinical signs.. Seroconversion was observed only in vaccinated heifers. These results indicate that, under the conditions of the present study, the gE vaccine virus did not cause any noticeable harmful effect on pregnant dams and on its offspring and did not spread horizontally among cattle. In the third chapter the pathogenicity of a US9 negative recombinant strain BoHV-1 using rabbits as an experimental model was avaluated. Rabbits four weeks old were divided in four groups (A, B, C, D) within four rabbits per group. Two groups were infected IN route and two via intraocular (IO). In each route, one group was infected by recombinant virus and the other infected by wild type (wt) virus. After IO infection, all rabbits developed intense conjunctivitis between days 3 to 10 pos infection (pi). Infective virus was consistently isolated from ocular swabs on days 1 to 10, reaching a maximum of 103.05 TCID50/mL. Animals infected in the IN rote with BoHV-1 wt, 4/4 rabbits showed characteristic signs of disease, which included pyrexia, apathy, anorexia, cough, severe nasal secretion between days 2 to 8. Rabbits inoculated with recombinant virus showed apathy, anorexia, nasal secretion (between days 3 and 7pi). Infectious virus was isolated in differents tissues as much as animals inoculated with wt and recombinant virus. Both virus were capable of replication in the mucosa nasal and ocular of the inoculated rabbits. Histopatological lesions were evident in both groups. In the present study showed which the US9 protein have not significantly in the pathogenicity in vivo.
|
4 |
Vacinologia e patogenicidade de amostras recombinantes de herpesvírus bovino tipo 1 (BoHV-1) / Vaccinology and pathogenicity of recombinants strains of the bovine herpesvirus type 1 (BoHV-1)Silva, Alessandra D'Avila da January 2007 (has links)
O herpesvírus bovino tipo 1 (BoHV-1) é um dos principais agentes causadores de prejuízos econômicos em criações de bovinos. A vacinação tem sido amplamente utilizada para minimizar as perdas causadas por infecções pelo BoHV-1. Dentre as vacinas disponíveis, as vacinas desenvolvidas a partir de amostras virais recombinantes apresentam a vantagem de permitirem a diferenciação entre animais infectados e imunizados. Anteriormente, foi desenvolvida uma vacina recombinante diferencial com uma amostra de BoHV-1 brasileira baseada na deleção do gene que codifica a glicoproteína E (gE). No primeiro capítulo do presente trabalho, a segurança e imunogenicidade desta vacina recombinante inativada foi avaliada. Os experimentos de imunização, desafio e reativação da vacina diferencial em animais experimentalmente inoculados demonstraram que a vacina recombinante foi segura e eficiente ao minimizar ou mesmo prevenir os efeitos da infecção pelo BoHV-1. No segundo capítulo, a segurança da vacina gE- foi avaliada, através da imunização intramuscular (IM) de 22 vacas (14 BoHV-1 soronegativas e 8 soropositivas) prenhes. Foi observada soroconverão, mas não abortos e nem anormalidades fetais nos animais imunizados. Na segunda parte do mesmo estudo foi analizada a capacidade do vírus recombinante difundir-se em um rebanho bovino. Quatro terneiros foram inoculados pela rota intranasal (IN) com a amostra recombinante gE- e, posteriormente, adicionados a outros 16 animais com mesma idade e semelhante condição corporal durante 180 dias. Todos os animais foram monitorados diariamente em busca de sintomatologia clínica. Foi observada soroconversão apenas nos animais imunizados. Estes resultados indicam que, nas condições deste estudo, a amostra recombinante não causou nenhum dano nas vacas prenhes ou em seus terneiros e não foi capaz de difundir-se horizontalmente no rebanho. No terceiro capítulo foi avaliada a patogenicidade de uma amostra recombinante de BoHV-1 com deleção no gene Us9, utilizando coelhos como modelo experimental. Coelhos com quatro semanas de idade foram divididos em quatro grupos (A, B, C, D). Dois grupos (A e B) foram infectados via intranasal (IN) e dois (C e D) infectados via intraocular (IO). Em cada via de infecção, um grupo foi infectado com o vírus recombinante e o outro com o vírus selvagem (wt). Após a infecção IO, todos os animais, de ambos os grupos, desenvolveram intensa conjuntivite entre os dias 3 a 10 pós-inoculação (pi). Vírus infeccioso foi consistentemente isolado a partir dos suabes oculares entre os dias 1 a 10 pi chegando a um título máximo de 103,05 TCID50/mL. Nos grupos infectados pela via IN com BoHV-1 wt, 4/4 coelhos apresentaram sintomatologia característica da doença, tais como: pirexia, apatia, anorexia, tosse, secreção nasal severa (entre os dias 2 e 8 pi). Animais inoculados com o recombinante apresentaram apatia, anorexia e descarga nasal (entre os dias 3 e 7 pi). Vírus infeccioso foi isolado em diversos tecidos tanto nos animais inoculados com o vírus wt como recombinante. Ambos os vírus foram capazes de replicar nas mucosas. Análises histológicas dos tecidos dos animais demonstraram lesões em ambos os grupos. Este estudo apresentou que a proteína Us9 não tem um papel significante na patogenicidade in vivo. / Bovine herpesvirus type 1 (BoHV-1) is an the major cause of losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. Vacines developed from recombinant strains have the advantage of allow the differentiation between immunized and infected animals. Previously, a recombinant differential BoHV-1 vaccine based on a glycoprotein E deleted (gE) virus was developed. In the first chapter of the present work, the safety and immunogenicity of such recombinant, as a inactivate vaccine, was evaluated. The experiments showed that the DIVA vaccinne was safe and efficient in order to minimize or even prevent the clinical signs of the infection by BoHV- 1. In the second chapter of the present study, the safety of the gE- vaccine during pregnancy was evaluated by the intramuscular inoculation into 22 pregnant dams (14 BoHV-1 seronegative; 8 seropositive). Seroconversion was detected but no abortions, stillbirths or fetal abnormalities were seen after vaccination. In the second part of the same study, the potential of the gE- vaccine virus to spread among beef cattle under field conditions was examined. Four heifers were inoculated intranasally (IN) with the gE- vaccine and mixed with other 16 animals at the same age and body conditions, for 180 days. All animals were daily monitored for clinical signs.. Seroconversion was observed only in vaccinated heifers. These results indicate that, under the conditions of the present study, the gE vaccine virus did not cause any noticeable harmful effect on pregnant dams and on its offspring and did not spread horizontally among cattle. In the third chapter the pathogenicity of a US9 negative recombinant strain BoHV-1 using rabbits as an experimental model was avaluated. Rabbits four weeks old were divided in four groups (A, B, C, D) within four rabbits per group. Two groups were infected IN route and two via intraocular (IO). In each route, one group was infected by recombinant virus and the other infected by wild type (wt) virus. After IO infection, all rabbits developed intense conjunctivitis between days 3 to 10 pos infection (pi). Infective virus was consistently isolated from ocular swabs on days 1 to 10, reaching a maximum of 103.05 TCID50/mL. Animals infected in the IN rote with BoHV-1 wt, 4/4 rabbits showed characteristic signs of disease, which included pyrexia, apathy, anorexia, cough, severe nasal secretion between days 2 to 8. Rabbits inoculated with recombinant virus showed apathy, anorexia, nasal secretion (between days 3 and 7pi). Infectious virus was isolated in differents tissues as much as animals inoculated with wt and recombinant virus. Both virus were capable of replication in the mucosa nasal and ocular of the inoculated rabbits. Histopatological lesions were evident in both groups. In the present study showed which the US9 protein have not significantly in the pathogenicity in vivo.
|
5 |
Vacinologia e patogenicidade de amostras recombinantes de herpesvírus bovino tipo 1 (BoHV-1) / Vaccinology and pathogenicity of recombinants strains of the bovine herpesvirus type 1 (BoHV-1)Silva, Alessandra D'Avila da January 2007 (has links)
O herpesvírus bovino tipo 1 (BoHV-1) é um dos principais agentes causadores de prejuízos econômicos em criações de bovinos. A vacinação tem sido amplamente utilizada para minimizar as perdas causadas por infecções pelo BoHV-1. Dentre as vacinas disponíveis, as vacinas desenvolvidas a partir de amostras virais recombinantes apresentam a vantagem de permitirem a diferenciação entre animais infectados e imunizados. Anteriormente, foi desenvolvida uma vacina recombinante diferencial com uma amostra de BoHV-1 brasileira baseada na deleção do gene que codifica a glicoproteína E (gE). No primeiro capítulo do presente trabalho, a segurança e imunogenicidade desta vacina recombinante inativada foi avaliada. Os experimentos de imunização, desafio e reativação da vacina diferencial em animais experimentalmente inoculados demonstraram que a vacina recombinante foi segura e eficiente ao minimizar ou mesmo prevenir os efeitos da infecção pelo BoHV-1. No segundo capítulo, a segurança da vacina gE- foi avaliada, através da imunização intramuscular (IM) de 22 vacas (14 BoHV-1 soronegativas e 8 soropositivas) prenhes. Foi observada soroconverão, mas não abortos e nem anormalidades fetais nos animais imunizados. Na segunda parte do mesmo estudo foi analizada a capacidade do vírus recombinante difundir-se em um rebanho bovino. Quatro terneiros foram inoculados pela rota intranasal (IN) com a amostra recombinante gE- e, posteriormente, adicionados a outros 16 animais com mesma idade e semelhante condição corporal durante 180 dias. Todos os animais foram monitorados diariamente em busca de sintomatologia clínica. Foi observada soroconversão apenas nos animais imunizados. Estes resultados indicam que, nas condições deste estudo, a amostra recombinante não causou nenhum dano nas vacas prenhes ou em seus terneiros e não foi capaz de difundir-se horizontalmente no rebanho. No terceiro capítulo foi avaliada a patogenicidade de uma amostra recombinante de BoHV-1 com deleção no gene Us9, utilizando coelhos como modelo experimental. Coelhos com quatro semanas de idade foram divididos em quatro grupos (A, B, C, D). Dois grupos (A e B) foram infectados via intranasal (IN) e dois (C e D) infectados via intraocular (IO). Em cada via de infecção, um grupo foi infectado com o vírus recombinante e o outro com o vírus selvagem (wt). Após a infecção IO, todos os animais, de ambos os grupos, desenvolveram intensa conjuntivite entre os dias 3 a 10 pós-inoculação (pi). Vírus infeccioso foi consistentemente isolado a partir dos suabes oculares entre os dias 1 a 10 pi chegando a um título máximo de 103,05 TCID50/mL. Nos grupos infectados pela via IN com BoHV-1 wt, 4/4 coelhos apresentaram sintomatologia característica da doença, tais como: pirexia, apatia, anorexia, tosse, secreção nasal severa (entre os dias 2 e 8 pi). Animais inoculados com o recombinante apresentaram apatia, anorexia e descarga nasal (entre os dias 3 e 7 pi). Vírus infeccioso foi isolado em diversos tecidos tanto nos animais inoculados com o vírus wt como recombinante. Ambos os vírus foram capazes de replicar nas mucosas. Análises histológicas dos tecidos dos animais demonstraram lesões em ambos os grupos. Este estudo apresentou que a proteína Us9 não tem um papel significante na patogenicidade in vivo. / Bovine herpesvirus type 1 (BoHV-1) is an the major cause of losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. Vacines developed from recombinant strains have the advantage of allow the differentiation between immunized and infected animals. Previously, a recombinant differential BoHV-1 vaccine based on a glycoprotein E deleted (gE) virus was developed. In the first chapter of the present work, the safety and immunogenicity of such recombinant, as a inactivate vaccine, was evaluated. The experiments showed that the DIVA vaccinne was safe and efficient in order to minimize or even prevent the clinical signs of the infection by BoHV- 1. In the second chapter of the present study, the safety of the gE- vaccine during pregnancy was evaluated by the intramuscular inoculation into 22 pregnant dams (14 BoHV-1 seronegative; 8 seropositive). Seroconversion was detected but no abortions, stillbirths or fetal abnormalities were seen after vaccination. In the second part of the same study, the potential of the gE- vaccine virus to spread among beef cattle under field conditions was examined. Four heifers were inoculated intranasally (IN) with the gE- vaccine and mixed with other 16 animals at the same age and body conditions, for 180 days. All animals were daily monitored for clinical signs.. Seroconversion was observed only in vaccinated heifers. These results indicate that, under the conditions of the present study, the gE vaccine virus did not cause any noticeable harmful effect on pregnant dams and on its offspring and did not spread horizontally among cattle. In the third chapter the pathogenicity of a US9 negative recombinant strain BoHV-1 using rabbits as an experimental model was avaluated. Rabbits four weeks old were divided in four groups (A, B, C, D) within four rabbits per group. Two groups were infected IN route and two via intraocular (IO). In each route, one group was infected by recombinant virus and the other infected by wild type (wt) virus. After IO infection, all rabbits developed intense conjunctivitis between days 3 to 10 pos infection (pi). Infective virus was consistently isolated from ocular swabs on days 1 to 10, reaching a maximum of 103.05 TCID50/mL. Animals infected in the IN rote with BoHV-1 wt, 4/4 rabbits showed characteristic signs of disease, which included pyrexia, apathy, anorexia, cough, severe nasal secretion between days 2 to 8. Rabbits inoculated with recombinant virus showed apathy, anorexia, nasal secretion (between days 3 and 7pi). Infectious virus was isolated in differents tissues as much as animals inoculated with wt and recombinant virus. Both virus were capable of replication in the mucosa nasal and ocular of the inoculated rabbits. Histopatological lesions were evident in both groups. In the present study showed which the US9 protein have not significantly in the pathogenicity in vivo.
|
6 |
Atenuação e imunogenicidade de uma cepa recombinante do herpesvírus bovino tipo 5 defectiva na glicoproteína e e enzima timidina quinase / Attenuation and immunogenicity of a recombinant bovine herpesvirus 5 defective in glycoprotein e and thymidine kinaseAnziliero, Deniz 16 August 2010 (has links)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / The present study describes an investigation of the attenuation/virulence and immunogenicity of a recombinant BoHV-5, a candidate vaccine strain. The recombinant BoHV-5gE/TKΔ was constructed out of a Brazilian BoHV-5 strain (SV507/99) and contains deletions in glycoprotein E (gE) gene as antigenic marker - and thymidine kinase (TK) gene for attenuation. In Chapter 1, we investigated the attenuation and immunogenicity of the recombinant in calves. Eighty-to-ninety days old calves (n=6) inoculated intranasally (IN) with the recombinant virus (titer of 107.5 TCID50) showed no clinical signs, and shed low titers
of virus in nasal secretions. On day 30 post-infection (pi), all animals had neutralizing antibodies against BoHV-5, in titers from 4 to 8 and remained negative for antibodies to gE. Administration of dexamethasone (Dx) to four of these calves at day 42 pi (0.1mg/kg/day
during 5 days) did not result in virus shedding or increase in antibody titers, indicating lack of
viral reactivation. In a second experiment, intramuscular immunization (IM) of calves with 8 months of age (n=9) with the recombinant virus (107.5 TCID50/animal) did not result in virus shedding or clinical signs. Vaccinated animals developed neutralizing antibodies in titers from
2 to 8 at day 42 post-vaccination (PV) and remained negative for gE antibodies. Finally, 21 calves (approximately 10 months old) were vaccinated IM with the recombinant virus (107.3 TCID50). All vaccinated animals developed neutralizing antibodies in titers from 2 to 16
at day 30pv. A boost vaccination performed on those animals at day 240 pv resulted in a rapid and strong anamnestic antibody response, with VN titers reaching from 16 to 256 at day 14 post-booster. Serum samples of all animals remained negative for gE antibodies. Serum
samples from vaccinated animals showed cross-neutralizing activity against nine field isolates of BoHV-5 and eight of BoHV-1. Chapter 2 describes an investigation of the immunogenicity and protection conferred by the recombinant virus against homologous (BoHV-5) and heterologous challenge (BoHV-1). A group of nine calves seronegative for BoHV-5 were vaccinated IM in a dose of 107.5 TCID50 of the recombinant virus and eight animals were maintained as non vaccinated controls. All vaccinated animals seroconverted 14 days postvaccination (pv), with neutralizing antibody titers from 2 to 4. At day 42 post-vaccination (pv), the vaccinated animals and controls were challenged by IN instillation of BoHV-5 or BoHV-1 isolates. After challenge, the length and magnitude of virus shedding was reduced in vaccinated animals compared to controls in both groups (challenged with BoHV-1 and
BoHV-5). The vaccinated animals did not show systemic, respiratory or neurological clinical signs after challenge. Furthermore, the control animals challenged with BoHV-5 (n=4) developed severe neurological disease and were euthanized in extremis between days 13 and
14 post-challenge (pd). The challenge resulted in a strong and rapid anamnestic response in vaccinated animals, inducing neutralizing titers higher than in control animals. Antibodies to gE were detected only after challenge in both vaccinated and controls calves. These results indicate that recombinant BoHV-5 gE/TKΔ is an adequate candidate for a vaccine strain, with
an antigenic marker, since it is attenuated and immunogenic for calves and provides homologous and heterologous (BoHV-1) protection. / O presente trabalho descreve a atenuação/virulência e imunogenicidade de uma cepa recombinante do herpesvírus bovino tipo 5 (BoHV-5) candidata a cepa vacinal. O
recombinante BoHV-5gE/TKΔ foi construído a partir da cepa brasileira SV507/99 e contém deleções nos genes da glicoproteína E (gE) como marcador antigênico - e da enzima
timidina quinase (TK), para atenuação. No capítulo 1, investigou-se a atenuação e imunogenicidade do recombinante em bezerros. Bezerros com 80 a 90 dias de idade (n=6), inoculados pela via intranasal (IN) com o vírus recombinante (título de 107,5 TCID50) não apresentaram sinais clínicos, e excretaram títulos baixos de vírus nas secreções nasais. No dia 30 pós-infecção (pi), todos os animais possuíam anticorpos neutralizantes contra o BoHV-5, em títulos entre 4 e 8, permanecendo soronegativos para a gE. Administração de dexametasona (Dx) a quatro desses bezerros no dia 42 pi (0.1mg/kg/dia durante 5 dias) não
resultou em excreção viral ou em aumento dos títulos de anticorpos, indicando ausência de reativação viral. Em um segundo experimento, vacinação intramuscular (IM) de bezerros com 8 meses de idade (n=9) com o recombinante (107,5TCID50/animal) não resultou em excreção viral ou em manifestações clínicas. Os animais vacinados desenvolveram anticorpos neutralizantes em títulos de 2 a 8 no dia 42 pós-vacinação (PV) e permaneceram negativos para anticorpos anti-gE. Finalmente, 21 bezerros (aproximadamente 10 meses de idade) foram vacinados com o recombinante (107,3 TCID50) pela via IM. Todos os animais vacinados desenvolveram anticorpos neutralizantes em títulos de 2 a 16 no dia 30pv. Revacinação desses animais no dia 240 pv provocou uma resposta anamnéstica rápida e intensa, resultando em títulos neutralizantes entre 16 e 256 no dia 14 pós-revacinação. O soro de todos os animais permaneceu negativo para anticorpos contra a gE. Amostras de soro dos animais vacinados apresentaram atividade neutralizante cruzada frente a nove isolados de BoHV-5 e oito de
BoHV-1. O capítulo 2 relata uma investigação sobre a imunogenicidade e proteção conferida pelo vírus recombinante frente a desafio homólogo (BoHV-5) e heterólogo (BoHV-1). Para isso, nove bezerros soronegativos para o BoHV-5 foram vacinados pela via intramuscular com uma dose de 107,5DICC50 do vírus recombinante e oito animais foram mantidos como controle. Todos os animais vacinados soroconverteram aos 14 dias pós-vacinação (pv), apresentando títulos de anticorpos neutralizantes entre 2 e 4. No dia 42 pós-vacinação (pv), os animais vacinados e os controles foram desafiados pela inoculação intranasal (IN) de isolados de BoHV-5 ou de BoHV-1. Após o desafio, a excreção de vírus pelos animais vacinados foi reduzida em comparação com os não vacinados, nos dois grupos (desafiados com BoHV-1 e BoHV-5). Os animais vacinados também não apresentaram sinais clínicos sistêmicos, respiratórios ou neurológicos pós desafio. Por outro lado, os animais controles inoculados
com o BoHV-5 (n=4) desenvolveram doença neurológica severa e foram eutanasiados in extremis entre os dias 13 e 14 pós-desafio (pd). O desafio provocou uma resposta anamnéstica intensa e rápida nos animais vacinados, induzindo títulos neutralizantes superiores aos animais não vacinados. Anticorpos contra a gE foram detectados apenas após o desafio, tanto nos vacinados quanto nos controles. Esses resultados indicam que o recombinante BoHV-5
gE/TKΔ é um candidato adequado a cepa vacinal com marcador antigênico, pois é atenuado e imunogênico para bezerros, confere proteção homóloga e também contra o BoHV-1.
|
7 |
Dual Promoters Improve the Rescue of Recombinant Measles Virus in Human CellsChey, Soroth, Palmer, Juliane Maria, Doerr, Laura, Liebert, Uwe Gerd 09 May 2023 (has links)
Reverse genetics is a technology that allows the production of a virus from its complementary DNA (cDNA). It is a powerful tool for analyzing viral genes, the development of novel vaccines, and gene delivery vectors. The standard reverse genetics protocols are laborious, time-consuming, and inefficient for negative-strand RNA viruses. A new reverse genetics platform was established, which increases the recovery efficiency of the measles virus (MV) in human 293-3-46 cells. The novel features compared with the standard system involving 293-3-46 cells comprise (a) dual promoters containing the RNA polymerase II promoter (CMV) and the bacteriophage T7 promoter placed in uni-direction on the same plasmid to enhance RNA transcription; (b) three G nucleotides added just after the T7 promoter to increase the T7 RNA polymerase activity; and (c) two ribozymes, the hairpin hammerhead ribozyme (HHRz), and the hepatitis delta virus ribozyme (HDVrz), were used to cleavage the exact termini of the antigenome RNA. Full-length antigenome cDNA of MV of the wild type IC323 strain or the vaccine AIK-C strain was inserted into the plasmid backbone. Both virus strains were easily rescued from their respective cloned cDNA. The rescue efficiency increased up to 80% compared with the use of the standard T7 rescue system. We assume that this system might be helpful in the rescue of other human mononegavirales.
|
Page generated in 0.08 seconds